Peripheral Biomarkers of Parkinson's disease progression and pioglitazone Effects

Journal of Parkinson's Disease

Volumn 5, Issue 4, 2015, Pages 731-736

  Simon, David K ^a   Simuni, Tanya ^b   Elm, Jordan ^c   Clark Matott, Joanne ^a   Graebner, Allison K ^a   Baker, Liana ^d   Dunlop, Susan R ^e   Emborg, Marina ^f   Kamp, Cornelia ^d   Morgan, John C ^g   Ross, G Webster ^h   Sharma, Saloni ^d   Ravina, Bernard ⁱ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WISCONSIN   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ VOYAGER THERAPEUTICS   (United States)

Author keywords

8 hydroxydeoxyguanosine; 8OHdG; biomarker; cytokine; IL 6; inflammation; interleukin 6; oxidativestress; Parkinsons disease; PGC 1alpha; pioglitazone

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BIOLOGICAL MARKER; ESTROGEN RELATED RECEPTOR ALPHA; INTERLEUKIN 6; PEROXIREDOXIN 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; PLACEBO; RASAGILINE; SELEGILINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 8-OXO-7-HYDRODEOXYGUANOSINE; ANTIDIABETIC AGENT; DEOXYGUANOSINE; IL6 PROTEIN, HUMAN; PPARGC1A PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CYC GENE; DISEASE ASSOCIATION; DISEASE COURSE; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ERRA GENE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PRDX3 GENE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; INFLAMMATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; URINE;

AGED; BIOMARKERS; DEOXYGUANOSINE; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TREATMENT FAILURE;

EID: 84946603008     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-150666     Document Type: Article

References (34)

1. Beal MF, 2003 Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 991 120 131
2. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR, 2010 PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2 52ra73
3. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM, 2011 PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144 689 702
4. Siddiqui A, Chinta SJ, Mallajosyula JK, Rajagopolan S, Hanson I, Rane A, Melov S, Andersen JK, 2012 Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: Implications for Parkinson's disease. Free Radic Biol Med 53 993 1003
5. Clark J, Simon DK, 2009 Transcribe to Survive: Transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal 11 509 528
6. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, Montine TJ, 1999 Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154 1423 1429
7. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M, 2008 Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131 389 396
8. Migliore L, Petrozzi L, Lucetti C, Gambaccini G, Bernardini S, Scarpato R, Trippi F, Barale R, Frenzilli G, Rodilla V, Bonuccelli U, 2002 Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58 1809 1815
9. Chen CM, Liu JL, Wu YR, Chen YC, Cheng HS, Cheng ML, Chiu DT, 2009 Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Neurobiol Dis 33 429 435
10. Sato S, Mizuno Y, Hattori N, 2005 Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64 1081 1083
11. Gadient RA, Otten UH, 1997 Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog Neurobiol 52 379 390
12. Nagatsu T, Sawada M, 2005 Inflammatory process in Parkinson's disease: Role for cytokines. Curr Pharm Des 11 999 1016
13. Hofmann KW, Schuh AF, Saute J, Townsend R, Fricke D, Leke R, Souza DO, Portela LV, Chaves ML, Rieder CR, 2009 Interleukin-6 serum levels in patients with Parkinson's disease. Neurochem Res 34 1401 1404
14. Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O, 2012 Non-motor symptoms in patients with Parkinson's disease-correlations with inflammatory cytokines in serum. PLoS One 7 e47387
15. Pagel-Langenickel I, Bao J, Joseph JJ, Schwartz DR, Mantell BS, Xu X, Raghavachari N, Sack MN, 2008 PGC-1alpha integrates insulin signaling, mitochondrial regulation, and bioenergetic function in skeletal muscle. J Biol Chem 283 22464 22472
16. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R, 2009 PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 55 496 504
17. Wang Y, Ye S, Hu Y, Zhao L, Zheng M, 2013 The effect of hydrochloride pioglitazone on urinary 8-hydroxy -deoxyguanosine excretion in type 2 diabetics. J Diabetes Complications 27 75 77
18. Abe H, Mita T, Kudo K, Funayama T, Tokoro M, Kaga H, Ikeda F, Kanazawa A, Hirose T, Kawamori R, Watada H, 2009 Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy. Endocr J 56 911 913
19. Park SW, Yi JH, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, Vemuganti R, 2007 Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 320 1002 1012
20. Patzer A, Zhao Y, Stock I, Gohlke P, Herdegen T, Culman J, 2008 Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. Eur J Neurosci 28 1786 1794
21. Yu HC, Feng SF, Chao PL, Lin AM, 2010 Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system. Neuropathol Appl Neurobiol 36 612 622
22. Quinn LP, Crook B, Hows ME, Vidgeon-Hart M, Chapman H, Upton N, Medhurst AD, Virley DJ, 2008 The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br J Pharmacol 154 226 233
23. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC, 2002 Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 82 615 624
24. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB, 2004 Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88 494 501
25. Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, Kemnitz JW, Johnson JA, Emborg ME, 2011 The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 8 91
26. Ninds Exploratory Trials in Parkinson Disease FS-ZONE, Investigators 2015 Pioglitazone in early Parkinson's disease: A phase 2, multicentre, double-blind, randomised trial. Lancet Neurol 14 795 803
27. Thompson DK, Huffman KM, Kraus WE, Kraus VB, 2012 Critical appraisal of four IL-6 immunoassays. PLoS One 7 e30659
28. Shreeve N, Cagampang F, Sadek K, Tolhurst M, Houldey A, Hill CM, Brook N, Macklon N, Cheong Y, 2013 Poor sleep in PCOS; is melatonin the culprit? Hum Reprod 28 1348 1353
29. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA, 2000 Smoking, alcohol, and coffee consumption preceding Parkinson's disease: A case-control study. Neurology 55 1350 1358
30. Brauer R, Bhaskaran K, Chaturvedi N, Dexter DT, Smeeth L, Douglas I, 2015 Glitazone treatment and incidence of Parkinson's disease among people with diabetes: A retrospective cohort study. PLoS Med 12 e1001854
31. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM, 2006 Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127 397 408
32. Deleidi M, Gasser T, 2013 The role of inflammation in sporadic and familial Parkinson's disease. Cell Mol Life Sci 70 4259 4273
33. Hiramatsu S, Tajiri Y, Karashima T, 2004 Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients. Diabetes Obes Metab 6 231 233
34. Shimizu H, Oh IS, Tsuchiya T, Ohtani KI, Okada S, Mori M, 2006 Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: A randomized study. Diabet Med 23 253 257